Home
Resources
Publications
Validity of HB-EGF as Target for Human Neuroblastoma Therapy

Validity of HB-EGF as Target for Human Neuroblastoma Therapy

Sung Ouk Nam, Fusanori Yotsumoto, Kohei Miyata, Ryota Souzaki, Tomoaki Taguchi, Masahide Kuroki, Shingo Miyamoto

Anticancer Res. 2015 Aug;35(8):4433-40.

PMID: 26168483

Abstract:

Background/aim:
Neuroblastoma (NB) is the most common and lethal extracranial solid tumor in children. The present study aimed to verify that the heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a rational target in NB therapy.
Material and methods:
We examined expression of EGFR ligands in four NB cell lines using 2-dimensional culture (DC) and 3DC conditions. To assess the anti-tumor effect of cross-reacting material 197 (CRM197), which is a specific inhibitor of HB-EGF, on NB cells, we also performed terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay to detect apoptotic cells.
Results:
HB-EGF was predominantly expressed in two out of four NB cell lines under 2DC and 3DC conditions. CRM197 significantly induced apoptosis of NB cells with high HB-EGF expression.
Conclusion:
HB-EGF plays an important role in neuroblastoma tumorigenesis and CRM197 showed an effective antitumor effect in neuroblastoma cells.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
IAR42413234	HB-EGF human			Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: